These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29959059)

  • 1. Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
    Schunselaar LM; Monkhorst K; van der Noort V; Wijdeven R; Peters D; Zwart W; Neefjes J; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1577-1587. PubMed ID: 29959059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
    Smith RA; Zammit DJ; Damle NK; Usansky H; Reddy SP; Lin JH; Mistry M; Rao NS; Denis LJ; Gupta S
    Mol Cancer Ther; 2021 Aug; 20(8):1327-1337. PubMed ID: 34045226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
    Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
    Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.
    Boghaert ER; Sridharan L; Khandke KM; Armellino D; Ryan MG; Myers K; Harrop R; Kunz A; Hamann PR; Marquette K; Dougher M; DiJoseph JF; Damle NK
    Int J Oncol; 2008 Jan; 32(1):221-34. PubMed ID: 18097562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
    Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
    Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.
    Sapra P; Damelin M; Dijoseph J; Marquette K; Geles KG; Golas J; Dougher M; Narayanan B; Giannakou A; Khandke K; Dushin R; Ernstoff E; Lucas J; Leal M; Hu G; O'Donnell CJ; Tchistiakova L; Abraham RT; Gerber HP
    Mol Cancer Ther; 2013 Jan; 12(1):38-47. PubMed ID: 23223830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
    Nicolaides NC; Schweizer C; Somers EB; Wang W; Fernando S; Ross EN; Grasso L; Hassan R; Kline JB
    Cancer Biol Ther; 2018 Jul; 19(7):622-630. PubMed ID: 29652548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
    Maio M; Scherpereel A; Calabrò L; Aerts J; Perez SC; Bearz A; Nackaerts K; Fennell DA; Kowalski D; Tsao AS; Taylor P; Grosso F; Antonia SJ; Nowak AK; Taboada M; Puglisi M; Stockman PK; Kindler HL
    Lancet Oncol; 2017 Sep; 18(9):1261-1273. PubMed ID: 28729154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody drug conjugates in thoracic malignancies.
    Pacheco JM; Camidge DR
    Lung Cancer; 2018 Oct; 124():260-269. PubMed ID: 30268471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Mesothelioma Effusions Are Infiltrated by CD3
    Khanna S; Thomas A; Abate-Daga D; Zhang J; Morrow B; Steinberg SM; Orlandi A; Ferroni P; Schlom J; Guadagni F; Hassan R
    J Thorac Oncol; 2016 Nov; 11(11):1993-2005. PubMed ID: 27544053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography.
    Giddabasappa A; Gupta VR; Norberg R; Gupta P; Spilker ME; Wentland J; Rago B; Eswaraka J; Leal M; Sapra P
    Mol Cancer Ther; 2016 Oct; 15(10):2530-2540. PubMed ID: 27466353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trophoblast Glycoprotein (TPGB/5T4) in Human Placenta: Expression, Regulation, and Presence in Extracellular Microvesicles and Exosomes.
    Alam SMK; Jasti S; Kshirsagar SK; Tannetta DS; Dragovic RA; Redman CW; Sargent IL; Hodes HC; Nauser TL; Fortes T; Filler AM; Behan K; Martin DR; Fields TA; Petroff BK; Petroff MG
    Reprod Sci; 2018 Feb; 25(2):185-197. PubMed ID: 28481180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models.
    Wang R; Lai Q; Tang L; Tao Y; Yao Y; Liu Y; Lu Y; Shen C; Lu R; Fan C; Zhang R; Wang Y; Yu L; Yang T; Wu Y; Peng Y; Wei X; Fu Y; Lai W; Gou L; Yang J
    Am J Cancer Res; 2018; 8(4):610-623. PubMed ID: 29736307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer.
    Naganuma H; Kono K; Mori Y; Takayoshi S; Stern PL; Tasaka K; Matsumoto Y
    Anticancer Res; 2002; 22(2B):1033-8. PubMed ID: 12168897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
    Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5T4 oncofetal antigen expression in ovarian carcinoma.
    Wrigley E; McGown AT; Rennison J; Swindell R; Crowther D; Starzynska T; Stern PL
    Int J Gynecol Cancer; 1995 Jul; 5(4):269-274. PubMed ID: 11578488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4.
    Shaw DM; Embleton MJ; Westwater C; Ryan MG; Myers KA; Kingsman SM; Carroll MW; Stern PL
    Biochim Biophys Acta; 2000 Dec; 1524(2-3):238-46. PubMed ID: 11113573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.